A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.

Hdl Handle:
http://hdl.handle.net/10147/95637
Title:
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.
Authors:
Ford, Ian; Blauw, Gerard Jan; Murphy, Michael B; Shepherd, James; Cobbe, Stuart M; Bollen, Edward LEM; Buckley, Brendan M; Jukema, J Wouter; Hyland, Michael; Gaw, Allan; Lagaay, A Margot; Perry, Ivan J; Macfarlane, Peter; Norrie, John; Meinders, A Edo; Sweeney, Brian J; Packard, Chris J; Westendorp, Rudi GJ; Twomey, Cillian; Stott, David J
Affiliation:
University of Glasgow, Scotland. ian@stats.gla.ac.uk
Citation:
A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. 2002, 3 (1):8 Curr Control Trials Cardiovasc Med
Journal:
Current controlled trials in cardiovascular medicine
Issue Date:
20-May-2002
URI:
http://hdl.handle.net/10147/95637
DOI:
10.1186/1468-6708-3-8
PubMed ID:
12097148
Abstract:
BACKGROUND: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. METHODS: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. RESULTS: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). CONCLUSIONS: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.
ISSN:
1468-6694

Full metadata record

DC FieldValue Language
dc.contributor.authorFord, Ianen
dc.contributor.authorBlauw, Gerard Janen
dc.contributor.authorMurphy, Michael Ben
dc.contributor.authorShepherd, Jamesen
dc.contributor.authorCobbe, Stuart Men
dc.contributor.authorBollen, Edward LEMen
dc.contributor.authorBuckley, Brendan Men
dc.contributor.authorJukema, J Wouteren
dc.contributor.authorHyland, Michaelen
dc.contributor.authorGaw, Allanen
dc.contributor.authorLagaay, A Margoten
dc.contributor.authorPerry, Ivan Jen
dc.contributor.authorMacfarlane, Peteren
dc.contributor.authorNorrie, Johnen
dc.contributor.authorMeinders, A Edoen
dc.contributor.authorSweeney, Brian Jen
dc.contributor.authorPackard, Chris Jen
dc.contributor.authorWestendorp, Rudi GJen
dc.contributor.authorTwomey, Cillianen
dc.contributor.authorStott, David Jen
dc.date.accessioned2010-04-06T10:15:02Z-
dc.date.available2010-04-06T10:15:02Z-
dc.date.issued2002-05-20-
dc.identifier.citationA Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. 2002, 3 (1):8 Curr Control Trials Cardiovasc Meden
dc.identifier.issn1468-6694-
dc.identifier.pmid12097148-
dc.identifier.doi10.1186/1468-6708-3-8-
dc.identifier.urihttp://hdl.handle.net/10147/95637-
dc.description.abstractBACKGROUND: PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. METHODS: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition. RESULTS: In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0-9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women). CONCLUSIONS: Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.-
dc.languageENG-
dc.titleA Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics.en
dc.contributor.departmentUniversity of Glasgow, Scotland. ian@stats.gla.ac.uken
dc.identifier.journalCurrent controlled trials in cardiovascular medicineen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.